{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:15:19Z","timestamp":1792653319038,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ijbiomac.2020.06.115","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T02:07:54Z","timestamp":1592273274000},"page":"1086-1098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Recent update on discovery and development of Hsp90 inhibitors as senolytic agents"],"prefix":"10.1016","volume":"161","author":[{"given":"Sayan","family":"Dutta Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Ho","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tibs.2016.01.003","article-title":"Heat shock proteins promote cancer: it\u2019s a protection racket","volume":"41","author":"Calderwood","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2019.05.073","article-title":"Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer","volume":"178","author":"Dutta Gupta","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0015","doi-asserted-by":"crossref","first-page":"e0208287","DOI":"10.1371\/journal.pone.0208287","article-title":"The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity","volume":"14","author":"Echeverria","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(04)00229-7","article-title":"Hsp90 isoforms: functions, expression and clinical importance","volume":"562","author":"Sreedhar","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0025","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.2174\/1568026616666160413141154","article-title":"Paralog specific Hsp90 inhibitors - a brief history and a bright future","volume":"16","author":"T. Gewirth","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/2212796812666180405144003","article-title":"Hsp90 flexibility and development of its inhibitors for the treat ment of cancer","volume":"12","author":"Gupta","year":"2018","journal-title":"Curr. Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0035","series-title":"Med. Chem. With Pharm. Prod. Dev","first-page":"57","article-title":"Novel anti-cancer drugs based on Hsp90 inhibitory mechanisms: a recent report","author":"Dutta Gupta","year":"2019"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0040","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1016\/j.jmb.2019.06.004","article-title":"Conformational cycling within the closed state of Grp94, an Hsp90-family chaperone","volume":"431","author":"Huang","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0045","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-020-15050-0","article-title":"Conformational dynamics modulate the catalytic activity of the molecular chaperone Hsp90","volume":"11","author":"Mader","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbpa.2019.11.009","article-title":"Drugging histone methyltransferases in cancer","volume":"56","author":"Richart","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41467-017-02013-1","article-title":"Structure-guided design of an Hsp90beta N-terminal isoform-selective inhibitor","volume":"9","author":"Khandelwal","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141786","article-title":"Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced HSP90 isoforms and their conformationally restricted mutants","volume":"10","author":"Prince","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0065","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s12272-015-0636-1","article-title":"Organelle-specific Hsp90 inhibitors","volume":"38","author":"Seo","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166271","article-title":"Exploring the functional complementation between Grp94 and Hsp90","volume":"11","author":"Maharaj","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0075","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbamcr.2011.10.013","article-title":"GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum","volume":"1823","author":"Marzec","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molcel.2007.08.024","article-title":"Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones","volume":"28","author":"Dollins","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/acs.jctc.7b00766","article-title":"The structural asymmetry of mitochondrial Hsp90 (Trap1) determines fine tuning of functional dynamics","volume":"14","author":"Moroni","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0090","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1107\/S2059798316009906","article-title":"2.4 A resolution crystal structure of human TRAP1NM, the Hsp90 paralog in the mitochondrial matrix","volume":"72","author":"Sung","year":"2016","journal-title":"Acta Crystallogr. Sect. D, Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/B978-0-12-407697-6.00005-2","article-title":"Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally","volume":"303","author":"Li","year":"2013","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0100","doi-asserted-by":"crossref","DOI":"10.3791\/55533","article-title":"Techniques to Induce and Quantify Cellular Senescence","author":"Noren Hooten","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4000","article-title":"Cellular senescence in aging and age-related disease: from mechanisms to therapy","volume":"21","author":"Childs","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0110","doi-asserted-by":"crossref","first-page":"35509","DOI":"10.18632\/oncotarget.5899","article-title":"DNA damage response (DDR) and senescence: shuttled inflamma-miRNAs on the stage of inflamm-aging","volume":"6","author":"Olivieri","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0115","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.4155\/fmc-2018-0234","article-title":"The emerging field of senotherapeutic drugs","volume":"10","author":"Myrianthopoulos","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41467-017-00314-z","article-title":"Identification of HSP90 inhibitors as a novel class of senolytics","volume":"8","author":"Fuhrmann-Stroissnigg","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0125","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/ijc.25511","article-title":"The ARF tumor suppressor: structure, functions and status in cancer","volume":"127","author":"Ozenne","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0130","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-05-2378","article-title":"Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant","volume":"66","author":"Colombo","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/35074506","article-title":"Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus","volume":"3","author":"Llanos","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0140","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cell.2005.03.037","article-title":"ARF-BP1\/mule is a critical mediator of the ARF tumor suppressor","volume":"121","author":"Chen","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4161\/cc.5.7.2625","article-title":"p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation","volume":"5","author":"Eymin","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0150","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1097-2765(03)00431-3","article-title":"Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation","volume":"12","author":"Itahana","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0155","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/embor.2009.139","article-title":"ARF stimulates XPC to trigger nucleotide excision repair by regulating the repressor complex of E2F4","volume":"10","author":"Dominguez-Brauer","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-07-2069","article-title":"p53-dependent and p53-independent activation of autophagy by ARF","volume":"68","author":"Abida","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0165","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1038\/sj.onc.1206851","article-title":"MDM2-ARF complex regulates p53 sumoylation","volume":"22","author":"Chen","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0170","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1101\/gad.510809","article-title":"The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence","volume":"23","author":"Agger","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/0008-5472.CAN-16-0613","article-title":"Molecular chaperone HSP90 is necessary to prevent cellular senescence via lysosomal degradation of p14ARF","volume":"77","author":"Han","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0180","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1134\/S0006297910130055","article-title":"Telomerase: structure, functions, and activity regulation","volume":"75","author":"Zvereva","year":"2010","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0185","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3892\/ijo.2012.1611","article-title":"Telomere structure and telomerase in health and disease (review)","volume":"41","author":"Gomez","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0190","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1873-3468.13084","article-title":"Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis","volume":"592","author":"Hannen","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0195","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/carcin\/bgn225","article-title":"Association of hsp90 to the hTERT promoter is necessary for hTERT expression in human oral cancer cells","volume":"29","author":"Kim","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/genes7090064","article-title":"Telomerase regulation from beginning to the end","volume":"7","author":"MacNeil","year":"2016","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fgene.2015.00094","article-title":"DDR-mediated crosstalk between DNA-damaged cells and their microenvironment","volume":"6","author":"Malaquin","year":"2015","journal-title":"Front. Genet."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12192-017-0843-4","article-title":"Heat shock proteins and DNA repair mechanisms: an updated overview","volume":"23","author":"Sottile","year":"2018","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0215","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1073\/pnas.1203326109","article-title":"BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2\/M checkpoint activation","volume":"109","author":"Stecklein","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-6670-7_9","article-title":"Detecting the senescence-associated secretory phenotype (SASP) by high content microscopy analysis","volume":"1534","author":"Hari","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.exger.2016.05.010","article-title":"Keeping the senescence secretome under control: molecular reins on the senescence-associated secretory phenotype","volume":"82","author":"Malaquin","year":"2016","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0230","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41388-017-0044-8","article-title":"HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome","volume":"37","author":"di Martino","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0235","first-page":"300038","article-title":"Modulation of mitochondrial Hsp90 (TRAP1) ATPase activity by calcium and magnesium","author":"Elnatan","year":"2018","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070686","article-title":"Mitochondrial homeostasis and cellular senescence","volume":"8","author":"Vasileiou","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fonc.2017.00058","article-title":"The chaperone TRAP1 as a modulator of the mitochondrial adaptations in cancer cells","volume":"7","author":"Masgras","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0250","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12192-016-0687-3","article-title":"Past, present, and emerging roles of mitochondrial heat shock protein TRAP1 in the metabolism and regulation of cancer stem cells","volume":"21","author":"Im","year":"2016","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0255","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/15384101.2018.1475828","article-title":"Hsp90 inhibitors as senolytic drugs to extend healthy aging","volume":"17","author":"Fuhrmann-Stroissnigg","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0260","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1083\/jcb.201003138","article-title":"Regulation of basal cellular physiology by the homeostatic unfolded protein response","volume":"189","author":"Rutkowski","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/febs.14522","article-title":"ER stress and unfolded protein response in ocular health and disease","volume":"286","author":"Kroeger","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.acr.2015.09.001","article-title":"GRP94\/gp96 in cancer: biology, structure, immunology, and drug development","volume":"129","author":"Wu","year":"2016","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0275","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.2174\/1568026616666160413141613","article-title":"Clients and oncogenic roles of molecular chaperone gp96\/grp94","volume":"16","author":"A. Ansa-Addo","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0280","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","article-title":"Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1","volume":"94","author":"Zou","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0285","doi-asserted-by":"crossref","first-page":"45791","DOI":"10.1074\/jbc.M105931200","article-title":"Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex","volume":"276","author":"Guo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0290","doi-asserted-by":"crossref","first-page":"31767","DOI":"10.18632\/oncotarget.5167","article-title":"Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia","volume":"6","author":"Ganguly","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0295","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1139\/O09-049","article-title":"Modulation of Hsf1 activity by novobiocin and geldanamycin","volume":"87","author":"Conde","year":"2009","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0300","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1474-9726.2012.00827.x","article-title":"The heat shock transcription factor Hsf1 is downregulated in DNA damage-associated senescence, contributing to the maintenance of senescence phenotype","volume":"11","author":"Kim","year":"2012","journal-title":"Aging Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0305","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0310","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","article-title":"Senolytics improve physical function and increase lifespan in old age","volume":"24","author":"Xu","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0315","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm980403y","article-title":"Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin","volume":"42","author":"Roe","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0320","first-page":"369","article-title":"Rational identification of Hsp90 inhibitors as anticancer lead molecules by structure based drug designing approach, anticancer","volume":"20","author":"Gupta","year":"2020","journal-title":"Agents Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0325","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1074\/jbc.272.7.4013","article-title":"The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase","volume":"272","author":"Stancato","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0330","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)80203-2","article-title":"Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent","volume":"89","author":"Stebbins","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0335","doi-asserted-by":"crossref","DOI":"10.1007\/s11046-019-00370-7","article-title":"In vitro interaction of geldanamycin with triazoles and echinocandins against common and emerging candida species","author":"Mahmoudi","year":"2019","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0340","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0092-8674(03)01027-4","article-title":"The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37)","volume":"116","author":"Roe","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0345","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","article-title":"Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo","volume":"4","author":"Debacq-Chainiaux","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0350","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00689048","article-title":"Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent","volume":"36","author":"Supko","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0355","first-page":"716","article-title":"Advances in antitumor activity of the hsp90 inhibitor geldanamycin","volume":"36","author":"Liao","year":"2001","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0360","doi-asserted-by":"crossref","first-page":"22796","DOI":"10.1074\/jbc.271.37.22796","article-title":"Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin","volume":"271","author":"Mimnaugh","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0365","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ab.2003.10.038","article-title":"High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity","volume":"327","author":"Rowlands","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011076","article-title":"Induction of premature senescence by hsp90 inhibition in small cell lung cancer","volume":"5","author":"Restall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0380","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2174\/156652409788488757","article-title":"17 AAG for HSP90 inhibition in cancer--from bench to bedside","volume":"9","author":"Usmani","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0385","unstructured":"Tanespimycin (17-AAG), (n.d.). https:\/\/www.selleckchem.com\/products\/17-AAG(Geldanamycin).html (accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0390","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-04-2322","article-title":"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers","volume":"11","author":"Ramanathan","year":"2005","journal-title":"Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0395","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10637-010-9493-4","article-title":"A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma","volume":"30","author":"Pacey","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0400","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1158\/1078-0432.CCR-11-0072","article-title":"HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab","volume":"17","author":"Modi","year":"2011","journal-title":"Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0405","article-title":"Heat shock protein 90: its inhibition and function","volume":"373","author":"Zuehlke","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0410","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm0603116","article-title":"Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90","volume":"49","author":"Ge","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0415","unstructured":"Alvespimycin (17-DMAG) HCl, (n.d.). https:\/\/www.selleckchem.com\/products\/17-DMAG,Hydrochloride-Salt.html (accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0420","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-1-4939-7477-1_29","article-title":"Clinical evaluation and biomarker profiling of Hsp90 inhibitors","volume":"1709","author":"Yuno","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0425","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/leu.2009.292","article-title":"Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia","volume":"24","author":"Lancet","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/15748928113089990031","article-title":"HSP90 inhibitors: current development and potential in cancer therapy","volume":"9","author":"Sidera","year":"2014","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0435","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/cdd.2012.93","article-title":"Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm","volume":"20","author":"Lee","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0440","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2012.07.005","article-title":"7-Aminoactinomycin D for apoptosis staining in flow cytometry","volume":"429","author":"Zembruski","year":"2012","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0445","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","article-title":"Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer","volume":"18","author":"Shimamura","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0450","first-page":"1849","article-title":"Ganetespib: research and clinical development","volume":"8","author":"Jhaveri","year":"2015","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0455","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: translating preclinical hypotheses into clinical promise","volume":"74","author":"Proia","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0460","unstructured":"Ganetespib (STA-9090), (n.d.). https:\/\/www.selleckchem.com\/products\/ganetespib-sta-9090.html (accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0465","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-13-152","article-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","volume":"13","author":"Goldman","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0470","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.19.00816","article-title":"Randomized phase III study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small-cell lung cancer (GALAXY-2)","volume":"38","author":"Pillai","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0475","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/annonc\/mdv220","article-title":"A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)","volume":"26","author":"Ramalingam","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0485","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1349-7006.2011.02191.x","article-title":"The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer","volume":"103","author":"Graham","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0490","unstructured":"Onalespib (AT13387), (n.d.). https:\/\/www.selleckchem.com\/products\/at13387.html (accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0495","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1021\/jm100060b","article-title":"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design","volume":"53","author":"Woodhead","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0500","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-14-0979","article-title":"First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0510","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1476-4598-12-128","article-title":"A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation","volume":"12","author":"Chan","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044642","article-title":"Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors","volume":"7","author":"Sharp","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0520","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","article-title":"NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis","volume":"68","author":"Eccles","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0525","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1349-7006.2011.01944.x","article-title":"Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins","volume":"102","author":"Lee","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0530","first-page":"1197","article-title":"Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma","volume":"31","author":"Okui","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0535","unstructured":"Luminespib (AUY-922, NVP-AUY922), (n.d.). https:\/\/www.selleckchem.com\/products\/NVP-AUY922.html (accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0540","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/cncr.29339","article-title":"Phase 1\/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma","volume":"121","author":"Seggewiss-Bernhardt","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0545","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07357907.2016.1193746","article-title":"A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors","volume":"34","author":"Bendell","year":"2016","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0550","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00280-016-3102-y","article-title":"A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer","volume":"78","author":"Renouf","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0555","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","article-title":"BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90","volume":"8","author":"Lundgren","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0560","first-page":"3","article-title":"BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (review)","volume":"40","author":"He","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0565","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/ijc.24825","article-title":"BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance","volume":"126","author":"Zhang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0570","unstructured":"BIIB021, (n.d.). https:\/\/www.selleckchem.com\/products\/BIIB021.html(accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm9004708","article-title":"Heat shock protein 90: inhibitors in clinical trials","volume":"53","author":"Biamonte","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0580","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1158\/1078-0432.CCR-13-1257","article-title":"A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors","volume":"20","author":"Saif","year":"2014","journal-title":"Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0585","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1021\/jm060297x","article-title":"Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors","volume":"49","author":"Immormino","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0590","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0508078","article-title":"Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90","volume":"49","author":"He","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0595","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0600","unstructured":"PU-H71, (n.d..). https:\/\/www.selleckchem.com\/products\/pu-h71.html (accessed April 1, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0605","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10637-017-0495-3","article-title":"First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile","volume":"36","author":"Speranza","year":"2018","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0610","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2015.06.007","article-title":"PU-H71: an improvement on nature\u2019s solutions to oncogenic Hsp90 addiction","volume":"99","author":"Trendowski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2012.10.008","article-title":"The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE","volume":"255","author":"Lisi","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0620","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/1535-7163.MCT-10-0055","article-title":"Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800","volume":"9","author":"Massey","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0625","unstructured":"NVP-BEP800, (n.d.). https:\/\/www.selleckchem.com\/products\/NVP-BEP800.html (accessed January 20, 2020)."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0630","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1535-7163.MCT-11-0667","article-title":"The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo","volume":"11","author":"Menezes","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0635","doi-asserted-by":"crossref","first-page":"18336","DOI":"10.1074\/jbc.M211309200","article-title":"Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes","volume":"278","author":"Banumathy","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0640","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1326-5-24","article-title":"Heat shock protein 90 in neurodegenerative diseases","volume":"5","author":"Luo","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0645","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1128\/AAC.02576-14","article-title":"Hsp90 inhibitors as new leads to target parasitic diarrheal diseases","volume":"58","author":"Debnath","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01799-17","article-title":"Identification of Hsp90 inhibitors with anti-plasmodium activity","volume":"62","author":"Posfai","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0655","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.1074\/jbc.M116.717538","article-title":"Inhibition of heat shock protein 90 prevents HIV rebound","volume":"291","author":"Joshi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2020.06.115_bb0660","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1016\/j.bmcl.2017.10.036","article-title":"Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases","volume":"27","author":"Vo","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813020335601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813020335601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:20:37Z","timestamp":1758874837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813020335601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":129,"alternative-id":["S0141813020335601"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.06.115","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent update on discovery and development of Hsp90 inhibitors as senolytic agents","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.06.115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}